Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 1002 to 1051 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1002\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"FUMARATE HYDRATASE, MITOCHONDRIAL PRECURSOR (EC 4.2.1.2) (FUMARASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.131317\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.51515\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.25491022\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FH\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1003\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HUNTINGTIN INTERACTING PROTEIN E; HUNTINGTIN INTERACTOR PROTEIN E. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0281805\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.110551\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.254909499\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1004\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROBABLE SERINE/THREONINE-PROTEIN KINASE KIAA0537 (EC 2.7.1.-). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.139695\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.54802\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.25490858\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NUAK1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1005\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DEOXYHYPUSINE SYNTHASE (EC 2.5.1.46) (DHS). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.138205\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.542366\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.254818702\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DHPS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1006\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ORPHAN NUCLEAR RECEPTOR TR2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.211877\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.831867\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.254700571\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NR2C1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1007\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ORPHAN NUCLEAR RECEPTOR NR2E1 (NUCLEAR RECEPTOR TLX) (TAILLESS HOMOLOG) (TLL) (HTLL). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.280845\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.10266\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.254697731\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NR2E1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1008\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRAF AND TNF RECEPTOR-ASSOCIATED PROTEIN; ETS1-ASSOCIATED PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.228495\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.897587\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.254565853\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TTRAP\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1009\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0413585\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.162467\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.254565543\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C20orf72\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1010\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PUTATATIVE 28 KDA PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.222495\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.87407\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.254550551\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PNO1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1011\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SORTING NEXIN 5. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.317621\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.24807\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.254489732\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SNX5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1012\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BETA-CATENIN (PRO2286). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.126011\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.495862\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.25412514\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CTNNB1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1013\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION INITIATION FACTOR TFIID 28 KDA SUBUNIT (TAFII-28) (TAFII28) (TFIID SUBUNIT P30-BETA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.343318\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.35164\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.254001065\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TAF11\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1014\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HIV-1 REV BINDING PROTEIN-LIKE; REV/REX ACTIVATION DOMAIN BINDING PROTEIN-RELATED. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0736761\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.290228\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253855934\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HRBL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1015\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
INTERSECTIN 2 (SH3 DOMAIN-CONTAINING PROTEIN 1B) (SH3P18) (SH3P18-LIKE WASP ASSOCIATED PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.079717\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.314025\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253855585\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1016\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PRAM-1 PROTEIN; PML-RARA TARGET GENE ENCODING AN ADAPTOR MOLECULE-1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.2316\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.91233\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253855513\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PRAM1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1017\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUCLEOPORIN-LIKE PROTEIN RIP (HIV-1 REV-BINDING PROTEIN) (REV INTERACTING PROTEIN) (REV/REX ACTIVATION DOMAIN-BINDING PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0957789\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.377297\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253855451\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HRB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1018\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CGTHBA PROTEIN (-14 GENE PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0593831\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.233925\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253855296\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C16orf35\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1019\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
INTERSECTIN 1 (SH3 DOMAIN-CONTAINING PROTEIN 1A) (SH3P17). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0927584\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.365399\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253855101\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1020\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HIV TAT SPECIFIC FACTOR 1; COFACTOR REQUIRED FOR TAT ACTIVATION OF HIV-1 TRANSCRIPTION. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0333753\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.131474\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253854755\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HTATSF1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1021\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"FTSJ HOMOLOG 3; LIKELY ORTHOLOG OF MOUSE ECTOPLACENTAL CONE, INVASIVE TROPHOBLAST GIANT CELLS, EXTRAEMBRYONIC ECTODERM AND CHORION SEQUENCE 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.280943\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.10792\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253576973\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FTSJ3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1022\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.178897\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.705791\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.25347022\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TBC1D10B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1023\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SHORT TRANSIENT RECEPTOR POTENTIAL CHANNEL 4 (TRPC4) (TRP-RELATED PROTEIN 4) (HTRP-4) (HTRP4). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.185352\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.731277\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253463462\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TRPC4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1024\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UBIQUITIN-LIKE PROTEIN SMT3B (SENTRIN 2) (HSMT3). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0979873\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.386626\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253442086\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1025\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ACRC PROTEIN; PUTATIVE NUCLEAR PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0649343\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.256212\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.25343973\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ACRC\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1026\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SHORT TRANSIENT RECEPTOR POTENTIAL CHANNEL 5 (TRPC5) (HTRP-5) (HTRP5). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.2166\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.854644\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.253438859\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
TRPC5\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1027\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EBP50-PDZ INTERACTOR OF 64 KDA (EPI64 PROTEIN). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
TBC1D10A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1028\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UBIQUITIN-LIKE PROTEIN SMT3A. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.101711\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.401325\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253437987\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SUMO3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1029\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE M2 CHAIN (EC 1.17.4.1) (RIBONUCLEOTIDE REDUCTASE SMALL CHAIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.282811\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.11593\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253430771\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RRM2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1030\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RETINOBLASTOMA-LIKE PROTEIN 2 (130 KDA RETINOBLASTOMA-ASSOCIATED PROTEIN) (PRB2) (P130) (RBR-2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.152107\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.600397\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253344037\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RBL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1031\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SODIUM/POTASSIUM-TRANSPORTING ATPASE ALPHA-2 CHAIN PRECURSOR (EC 3.6.3.9) (SODIUM PUMP 2) (NA+/K+ ATPASE 2). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.063502\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.250657\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.253342217\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATP1A2\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1032\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SODIUM/POTASSIUM-TRANSPORTING ATPASE ALPHA-1 CHAIN PRECURSOR (EC 3.6.3.9) (SODIUM PUMP 1) (NA+/K+ ATPASE 1). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
ATP1A1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1033\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CATHEPSIN L PRECURSOR (EC 3.4.22.15) (MAJOR EXCRETED PROTEIN) (MEP). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.184799\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.729445\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253341924\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CTSL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1034\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SODIUM/POTASSIUM-TRANSPORTING ATPASE ALPHA-3 CHAIN (EC 3.6.3.9) (SODIUM PUMP 3) (NA+/K+ ATPASE 3) (ALPHA(III)). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0735677\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.290389\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253341897\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATP1A3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1035\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CATHEPSIN L2 PRECURSOR (EC 3.4.22.43) (CATHEPSIN V) (CATHEPSIN U). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.163807\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.646587\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253341004\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CTSL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1036\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UNR PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0368889\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.145611\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.25333869\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CSDE1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1037\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LOH1CR12. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.147556\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.582446\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253338507\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LOH12CR1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1038\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RETINOBLASTOMA-LIKE PROTEIN 1 (107 KDA RETINOBLASTOMA-ASSOCIATED PROTEIN) (PRB1) (P107). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.128252\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.506251\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253336784\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RBL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1039\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HEAT SHOCK PROTEIN HSP 90-BETA (HSP 84) (HSP 90). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.341129\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.34662\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253322392\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HSP90AB1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1040\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ATP-DEPENDENT DNA HELICASE II, 70 KDA SUBUNIT (LUPUS KU AUTOANTIGEN PROTEIN P70) (KU70) (70 KDA SUBUNIT OF KU ANTIGEN) (THYROID-LUPUS AUTOANTIGEN) (TLAA) (CTC BOX BINDING FACTOR 75 KDA SUBUNIT) (CTCBF) (CTC75). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0397033\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.156754\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253284127\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1041\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAD17 HOMOLOG ISOFORM 1; RAD17-LIKE PROTEIN; CELL CYCLE CHECKPOINT PROTEIN (RAD17); RF-C ACTIVATOR 1 HOMOLOG. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0746521\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.294737\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253283775\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAD17\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1042\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ATP-DEPENDENT DNA HELICASE II, 80 KDA SUBUNIT (LUPUS KU AUTOANTIGEN PROTEIN P86) (KU86) (KU80) (86 KDA SUBUNIT OF KU ANTIGEN) (THYROID- LUPUS AUTOANTIGEN) (TLAA) (CTC BOX BINDING FACTOR 85 KDA SUBUNIT) (CTCBF) (CTC85) (NUCLEAR FACTOR IV) (DNA-REPAIR PROTE"\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.114355\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.451492\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.25328245\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
XRCC5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1043\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0327294\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.12923\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253264722\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TMEM87B\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1044\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.343832\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.3576\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253264585\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ASCC1\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1045\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0425806\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.168127\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253264496\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TMEM87A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1046\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HEAT SHOCK PROTEIN HSP 90-ALPHA (HSP 86). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.310662\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.22676\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.253237797\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HSP90AA2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1047\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SOLUBLE LIVER ANTIGEN/LIVER PANCREAS ANTIGEN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.293391\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.16068\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.252775097\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SEPSECS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1048\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ANNEXIN A11 (ANNEXIN XI) (CALCYCLIN-ASSOCIATED ANNEXIN 50) (CAP-50) (56 KDA AUTOANTIGEN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.114013\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.451047\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.252774101\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ANXA11\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1049\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CALMEGIN PRECURSOR. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0356563\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.14106\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.252773997\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CLGN\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1050\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CALNEXIN PRECURSOR (MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I ANTIGEN-BINDING PROTEIN P88) (P90) (IP90). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0429594\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.169952\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.252773724\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CANX\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1051\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RNA (GUANINE-7-) METHYLTRANSFERASE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0429379\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.169867\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.252773641\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RNMT\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/